Tag: ILL UMW USA NAM CHN ASA

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation

SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong...

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 4, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3....

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsILL UMW USA NAM CHN ASA

Government of Canada supports the 37th Francos de Montréal

FSK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Investor...

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

Tag: ILL UMW USA NAM CHN ASA

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us